Clinical trial simulation in drug development

被引:62
作者
Bonate, PL [1 ]
机构
[1] Quintiles, Clin Pharmacokinet, Kansas City, MO 64134 USA
关键词
Monte Carlo; computer assisted trial design; modeling;
D O I
10.1023/A:1007548719885
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Clinical trial simulation is the application of old technologies, e.g., Monte Carlo simulation, to a new problem, that problem being how to maximize the information content obtained during the drug development process with an intent to have the greatest chance of "success" in a clinical trial. When the information content of the drug is high. then simulation provides a method to synthesize that information into a coherent package that indicates the sponsor has good control over the pharmacology of the drug. From a purely financial point of view, what simulation offers pharmaceutical companies is the possibility of reducing the number of required studies, maximizing the chances for success in a clinical trial, and possibly shortening development time: all outcomes which will reduce drug development costs. The purpose of this paper is to introduce clinical trial simulation to the reader by discussing its potential in drug development, to briefly review the literature, and to make recommendations and caveats regarding its use.
引用
收藏
页码:252 / 256
页数:5
相关论文
共 16 条
[1]   THE EFFECT OF THERAPEUTIC TREATMENT CROSSOVERS ON THE POWER OF CLINICAL-TRIALS [J].
BARLOW, W ;
AZEN, S .
CONTROLLED CLINICAL TRIALS, 1990, 11 (05) :314-326
[2]  
*BOST CONS GROUP, 1993, ANAL PHARM MAN ASS
[3]   A SIMULATION STUDY USED TO DESIGN THE SEQUENTIAL MONITORING PLAN FOR A CLINICAL-TRIAL [J].
BROOKS, MM ;
HALLSTROM, A ;
PECKOVA, M .
STATISTICS IN MEDICINE, 1995, 14 (20) :2227-2237
[4]   DESIGNING A CLINICAL-TRIAL TO DEMONSTRATE PREVENTION OF ULCER RECURRENCE - MODELING SIMULATION APPROACHES [J].
ELASHOFF, JD ;
KOCH, GG ;
CHI, GYH .
STATISTICS IN MEDICINE, 1988, 7 (08) :877-888
[5]  
GAUTHIER M, 1997, APP CLIN TRIALS, V6, P22
[6]  
Gieschke R, 1997, INT J CLIN PHARM TH, V35, P469
[7]   SIMULATION AS A DESIGN TOOL FOR PHASE I/II CLINICAL-TRIALS - AN EXAMPLE FROM BONE-MARROW TRANSPLANTATION [J].
GOOLEY, TA ;
MARTIN, PJ ;
FISHER, LD ;
PETTINGER, M .
CONTROLLED CLINICAL TRIALS, 1994, 15 (06) :450-462
[8]   The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation [J].
Hale, MD ;
Nicholls, AJ ;
Bullingham, RES ;
Hené, R ;
Hoitsma, A ;
Squifflet, JP ;
Weimar, W ;
Vanrenterghem, Y ;
Van de Woude, FJ ;
Verpooten, GA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (06) :672-683
[9]  
Hale MD, 1996, APPL CLIN TRIALS, V5, P35
[10]  
Johnson SCD, 1998, DRUG INF J, V32, P961, DOI 10.1177/009286159803200414